CC
| |
CAXTON CORP13F | |
| CAXTON CORP | |
| Last update 2025-05-15 | 12 Stocks (0 new) |
| Value $5.00 Mil | Turnover 1 % |
CAXTON CORP Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RZLT | Rezolute Inc | 1,318,967 | 3,825.0 | 0% | 75.280 | 0% | 1.540 | +88.64% | +1.63% | 432.3 | Biotechnology | |
GLD | SPDR Gold Shares ETF | 1,298 | 374.1 | +11.04% | 7.360 | +0.73% | 0.000 | +12.30% | +26.94% | 102,386.4 | ||
BRK.B | Berkshire Hathaway Inc | 467 | 248.8 | -58.78% | 4.900 | -1.82% | 0.000 | -2.52% | +5.46% | 1,031,246.8 | Insurance | |
MNMD | Mind Medicine Inc | 34,073 | 199.3 | 0% | 3.920 | 0% | 0.050 | +32.60% | +3.45% | 544.0 | Biotechnology | |
BCAX | Bicara Therapeutics Inc | 10,941 | 142.6 | 0% | 2.810 | 0% | 0.020 | -5.26% | -48.28% | 491.4 | Biotechnology | |
CMPX | Compass Therapeutics Inc | 43,465 | 82.6 | 0% | 1.630 | 0% | 0.030 | +68.15% | +82.07% | 365.1 | Biotechnology | |
LXEO | Lexeo Therapeutics Inc | 17,851 | 61.9 | 0% | 1.220 | 0% | 0.050 | +153.63% | -31.00% | 150.7 | Biotechnology | |
KYTX | Kyverna Therapeutics Inc | 22,981 | 44.4 | 0% | 0.870 | 0% | 0.050 | +33.51% | -31.82% | 110.2 | Biotechnology | |
CRDF | Cardiff Oncology Inc | 13,287 | 41.7 | 0% | 0.820 | 0% | 0.020 | +35.69% | -15.90% | 242.8 | Biotechnology | |
IKT | Inhibikase Therapeutics Inc | 16,393 | 35.9 | 0% | 0.710 | 0% | 0.020 | +14.88% | -40.62% | 143.5 | Biotechnology |
CAXTON CORP's Historical Top Holdings Breakdowns
CAXTON CORP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
XERS | Xeris Biopharma Holdings Inc | 2025-03-31 | Sold Out Sold Out | -41.06% | 3.2 ($4.04) 5.87 | $4.70 | 16.34% | Sold Out | 0 | -2,015,157 | |
SPY | SPDR S&P 500 ETF Trust | 2025-03-31 | Sold Out Sold Out | -9.94% | 551.42 ($587.78) 612.93 | $620.68 | 5.60% | Sold Out | 0 | -2,823 | |
BRK.B | Berkshire Hathaway Inc | 2025-03-31 | Reduce Reduce | -1.82% | 442.66 ($486.15) 534.52 | $478.03 | -1.67% | Reduce -58.78% | 467 | -666 | |
GLD | SPDR Gold Shares ETF | 2025-03-31 | Add Add | +0.73% | 243.19 ($264.45) 288.14 | $307.37 | 16.23% | Add 11.04% | 1,298 | 129 | |
GLYC | GlycoMimetics Inc | 2025-03-31 | Sold Out Sold Out | -0.31% | 21 ($26.76) 35.9 | $15.70 | -41.33% | Sold Out | 0 | -203,578 | |
XERS | Xeris Biopharma Holdings Inc | 2024-12-31 | Reduce Reduce | -36.54% | 2.78 ($3.22) 3.73 | $4.70 | 45.96% | Reduce -60.59% | 2,015,157 | -3,098,191 | |
GLD | SPDR Gold Shares ETF | 2024-12-31 | New Buy New Buy | +1.70% | 236.59 ($245.74) 257.5 | $307.37 | 25.08% | New holding | 1,169 | 1,169 | |
ABVX | Abivax SA | 2024-12-31 | Sold Out Sold Out | -0.54% | 7.05 ($9.18) 10.69 | $7.95 | -13.40% | Sold Out | 0 | -11,365 | |
CRDF | Cardiff Oncology Inc | 2024-12-31 | New Buy New Buy | +0.35% | 2.31 ($3.14) 5.35 | $3.65 | 16.24% | New holding | 13,287 | 13,287 | |
IKT | Inhibikase Therapeutics Inc | 2024-12-31 | New Buy New Buy | +0.32% | 1.19 ($2.51) 3.97 | $1.93 | -23.11% | New holding | 16,393 | 16,393 |
CAXTON CORP Total Holding History ($B)
CAXTON CORP's Asset Allocation
CAXTON CORP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
CAXTON CORP's Hypothetical Growth since 2025-03-31
CAXTON CORP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
CAXTON CORP's Holdings Heat Map
Size field:
CAXTON CORP's Holdings Bubble Chart
CAXTON CORP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers